Meridian Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Expands line of enzyme immunoassay and fluorescent antibody offerings with purchase of Johnson & Johnson infectious disease products. In exchange for $3.3 mil. cash "plus inventory and additional future royalty payments," Meridian is gaining products to aid in the diagnosis of "certain viral diseases such as herpes, respiratory syncytial virus, chicken pox and certain serious bacterial infections such as chlamydia," a Jan. 26 release states. Annual sales from the line amount to about $5 mil. Under the terms of the deal, Meridian also "will manufacture certain products" for J&J's Ortho Diagnostic Systems
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.